Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2025; 17(12): 113387
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.113387
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.113387
Safety and efficacy of cryoablation in treating locally advanced pancreatic cancer
Li-Min Kang, A-Yong Wang, Ying-Hong Zhao, Lei Xu, Fa-Kun Yu, Fu-Wei Zhang, Department of Hepatobiliary and Pancreatic Surgery, Puer People’s Hospital, Puer 665000, Yunnan Province, China
Xiao-Long He, Clinical Medicine College, School of Medicine, Kunming University of Science and Technology, Kunming 650000, Yunnan Province, China
Li Lang, Department of Outpatient, Puer People’s Hospital, Puer 665000, Yunnan Province, China
Xian Wang, Yu-Hao Liu, Department of Cancer Center, Puer People’s Hospital, Puer 665000, Yunnan Province, China
Co-first authors: Li-Min Kang and Xiao-Long He.
Author contributions: Kang LM, Wang AY, Zhao YH, Xu L, Yu FK, and Zhang FW performed surgeries; Kang LM, Xu L, Yu FK, Lang L, Zhang FW, Wang X, and Liu YH collected the clinical and tumor data; Kang LM and He XL analyzed the data, wrote the paper, and contributed equally as co-first authors. All the authors have read and approved the final version.
Institutional review board statement: The study was received and approval by the Institutional review board of Puer People’s Hospital, No. 2024-001-05. All procedures were carried out in accordance with the Helsinki Declaration. All methods were carried out in accordance with relevant guidelines and regulations in the declaration.
Informed consent statement: Due to the retrospective nature of the study, informed consent was waived.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data generated or analyzed during this study are included in this published article. Further information can be obtained from the corresponding author on reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Min Kang, MD, PhD, Professor, Department of Hepatobiliary and Pancreatic Surgery, Puer People’s Hospital, No. 44 Zhenxing Street, Puer 665000, Yunnan Province, China. kanglimin2010@163.com
Received: August 25, 2025
Revised: September 28, 2025
Accepted: October 31, 2025
Published online: December 15, 2025
Processing time: 109 Days and 22.4 Hours
Revised: September 28, 2025
Accepted: October 31, 2025
Published online: December 15, 2025
Processing time: 109 Days and 22.4 Hours
Core Tip
Core Tip: Pancreatic cancer has an extremely poor prognosis. In particular, chemotherapy, targeted therapy, and immunotherapy may be ineffective for locally advanced pancreatic cancer (LAPC) because of its resistance to these modalities. In this retrospective study, 24 LAPC patients were treated with cryoablation at our hospital. The outcomes show that cryoablation can directly inactivate LAPC and boost immunity, thus delaying tumor progression, alleviating pain, improving quality of life, and prolonging survivals. Therefore, it is a safe and effective treatment option for LAPC that deserves wider adoption in clinical settings.